Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the U.S. for non-infectious uveitis affecting theposterior segment of the eye (NIU-PS).
0 ratings in the last 12 months
Visualize o retorno de longo prazo das ações. Dividendos e outros eventos são considerados.